Skip to main content
. Author manuscript; available in PMC: 2016 Sep 21.
Published in final edited form as: S Afr Med J. 2015 Sep 21;105(8):642–647. doi: 10.7196/samjnew.8794

Table 3.

Treatment, diabetes group

Medications
prescribed
All participants
(N=1 842)
n (%)
Subgroup with
HbA1c test (N=704)
n (%)
Controlled*
(N=160)
n (%)
Uncontrolled
(N=544)
n (%)
Hypoglycaemic medications
  No diabetes medications 119 (6.5) 33 (4.7) 23 (69.7) 10 (30.3)
  Metformin and/or sulfonylurea (but not insulin) 1 126 (61.1) 438 (62.2) 112 (25.6) 326 (74.4)
  Insulin (with/without oral agents) 588 (31.9) 230 (32.7) 25 (10.9) 205 (89.1)
  Missing information 9 (0.5)
Aspirin 1 155 (62.7) 477 (67.8) 101 (21.2) 376 (78.8)
Statin 931 (50.5) 407 (57.8) 82 (20.1) 325 (79.9)
ACE inhibitor 1 215 (66.0) 475 (67.5) 108 (22.7) 367 (77.3)

ACE = angiotensin-converting enzyme.

*

HbA1c <7%.

HbA1c ≥7%.